Urano Ayako, Hotta Mari, Ohwada Rina, Araki Mariko
Division of Endocrinology and Metabolism, Saitama Sekishinkai Hospital, Saitama, Japan.
Health Service Center, National Graduate Institute For Policy Studies, Tokyo, Japan; Institute of Women's Health, Tokyo Women's Medical University, Tokyo, Japan.
Clin Nutr. 2015 Jun;34(3):443-8. doi: 10.1016/j.clnu.2014.04.016. Epub 2014 May 28.
BACKGROUND & AIMS: Osteoporosis is a chief complication in patients with anorexia nervosa. Serum levels of undercarboxylated osteocalcin reflect serum and bone vitamin K deficiency. We investigated vitamin K status in patients with anorexia nervosa to help establish prevention and treatment recommendations for osteoporosis.
Fifty-four female amenorrheic patients with anorexia nervosa (29 restricting-type and 25 binge eating/purging type) (age, 28.0 (26.7-31.1) (mean (95% CI)) years; body mass index, 14.8 (14.1-15.5) kg/m(2), duration of illness; 107.3 (88.5-126.0) months) and 15 age-matched healthy females were included in this study. We measured serum levels of undercarboxylated osteocalcin, biochemical and nutritional markers, and bone metabolic markers. Dietary vitamin K intake was evaluated by a questionnaire.
Lumbar bone mineral density and T-scores in patients with anorexia nervosa were 0.756 (0.721-0.790) g/cm(2) and -2.4 (-2.1 to -2.7), respectively, indicating bone loss. Serum levels of undercarboxylated osteocalcin in patients with anorexia nervosa were significantly higher than those of controls. The 17% of restricting type and 40% of binge eating/purging type anorexia nervosa patients, serum levels of undercarboxylated osteocalcin were higher than 4.5 ng/ml and were diagnosed with vitamin K deficiency. Serum levels of undercarboxylated osteocalcin correlated significantly and negatively with vitamin K intake in patients with anorexia nervosa.
Patients with anorexia nervosa had vitamin K deficiency. Since a supplement of vitamin K might be effective for maintaining bone quality, we provide recommendations regarding vitamin K intake for prevention and treatment of osteoporosis in patients with AN.
骨质疏松症是神经性厌食症患者的主要并发症。血清未羧化骨钙素水平反映血清和骨骼维生素K缺乏情况。我们调查了神经性厌食症患者的维生素K状况,以帮助制定骨质疏松症的预防和治疗建议。
本研究纳入了54名神经性厌食症女性闭经患者(29名限制型和25名暴饮暴食/催吐型)(年龄28.0(26.7 - 31.1)(均值(95%置信区间))岁;体重指数14.8(14.1 - 15.5)kg/m²,病程107.3(88.5 - 126.0)个月)以及15名年龄匹配的健康女性。我们测量了血清未羧化骨钙素水平、生化和营养指标以及骨代谢指标。通过问卷调查评估膳食维生素K摄入量。
神经性厌食症患者的腰椎骨密度和T值分别为0.756(0.721 - 0.790)g/cm²和 - 2.4( - 2.1至 - 2.7),表明存在骨质流失。神经性厌食症患者的血清未羧化骨钙素水平显著高于对照组。17%的限制型和40%的暴饮暴食/催吐型神经性厌食症患者,血清未羧化骨钙素水平高于4.5 ng/ml,被诊断为维生素K缺乏。神经性厌食症患者血清未羧化骨钙素水平与维生素K摄入量显著负相关。
神经性厌食症患者存在维生素K缺乏。由于补充维生素K可能对维持骨骼质量有效,我们提供了关于维生素K摄入量的建议,用于神经性厌食症患者骨质疏松症的预防和治疗。